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ABSTRACT 
Mitogen-activated signaling pathways (MAPK) are one of the major and evolutionary 
conserved signaling pathways involved in protein phosphorylation. Inactivation of MAPK activity 
is attained by dephosphorylation of either the tyrosine or threonine residues, or both by the actions of 
MAP kinase phosphatase (MKPs). The prototype member of MKP family, MKP-1 is the most 
extensively studied MKP compared to ten other members in the group. Several mouse genetic and 
in vitro studies have established a key role for MKP-1 in the immune and metabolic systems. 
However, more recently there is growing body of literature suggesting important functions in the 
cardiovascular, nervous and musculoskeletal systems. With the development of tissue-specific knock-
out models most of these studies suggest MKP- 1 as potential therapeutic target in many disease 
conditions. 
Abbreviations: MAPK, mitogen-activated protein kinase; DUSP, dual-specificity 
phosphatase; MKP, MAP kinase phosphatase; ERK, extracellular-signal-regulated kinase; JNK, c-
jun N-terminal kinase; hVH, human vaccinia H1 phosphatase; PAC-1, phosphatase of activated cell 
1:MKB,MAPK-bindingF .-  ISSN: 
INTRODUCTION 
In Mammals, one of the major mechanisms used to 
transfer extracellular stimuli from the surface of the cell 
membrane to the nucleus is protein phosphorylation 
(Peti and Page 2013). One of the key and evolutionary 
conserved signaling pathways involved in protein 
phosphorylation is the mitogen-activated protein kinase 
(MAPK) signaling pathways.  Many MAPK signaling 
pathways exist in mammals in order to regulate an 
integrated response to a wide range of stimuli (Kyriakis 
and Avruch 2001, Tomida 2015). The classic three-
tiered cascade encompasses a MAPK, a MAPK kinase 
(MKK) and MAPK kinase kinase (MKKK). MAPK 
consists of three main groups; extracellular signal-
regulated kinases (ERK1/2), c-Jun N terminal kinases 
(JNK1/2/3), and p38 MAPK. Each of these groups of 
MAPK is activated by dual phosphorylation on Thr and 
Tyr residues within the activation motif (Thr-Xaa-Tyr) 
of the MAPK (Kyriakis and Avruch 2012). Once 
activated, a MAPK can phosphorylate a number of 
enzymes, transcription factors and other cytoskeleton 
proteins (Ebisuya, Kondoh et al. 2005).  
The inactivation of MAPK activity is achieved by 
dephosphorylation of either the tyrosine or threonine 
residues, or both by the actions of dual-specificity 
phosphatases (DUSPs) or MAP kinase phosphatases 
(MKPs).  
There are ten family members of MKPs that 
dephosphorylate MAPK on the Thr and Tyr residues 
with variable level of specificity (Keyse 2000, Farooq 
and Zhou 2004). DUSPs have a common structure that 
comprises of the MAPK-binding (MKB) domain in the 
N-terminal half and the dual-specificity phosphatase 
domain in the C-terminal half (Camps, Nichols et al. 
1998, Camps, Nichols et al. 2000). Classification of the 
MKPs has been established on substrate specificity, 
sequence similarity and subcellular distribution as 
shown in table 1 (Keyse 2008). There are three groups; 
type I which comprise of MKP-1/DUSP1, MKP-
2/DUSP4, PAC1/DUSP2 and hVH3/DUSP5 are 
located in the nucleus (Owens and Keyse 2007). Type 
II encompasses MKP-3/DUSP6, MKP-X/DUSP7 and 
MKP-4/DUSP9 that selectively dephosphorylate ERK 
and they are localized in the cytosol. And type III 
include MKP-5/DUSP10, MKP-7/DUSP16, and 
hVH5/DUSP8, they dephosphorylate JNK and p38 but  
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Table 1: Classification and Features of dual-specificity phosphatases 
 
Gene name  Alternative names           Subcellular localization  Substrate specificity Physiological roles References 
DUSP1 MKP-1, CL100, hVH-
1, erp 
Nuclear p38 MAPK, 
JNK>>ERK  
Regulator of immune function, 
cytokine secretion and  
Metabolic homeostasis 
(Chi, Barry et 
al. 2006, Wu, 
Roth et al. 
2006, Lawan, 
Zhang et al. 
2015) 
DUSP2      PAC-1                                                      Nuclear ERK>>p38 MAPK, 
JNK  






DUSP4      MKP-2, TYP2, hVH2, 
STY8  
Nuclear ERK, JNK>p38 
MAPK         
Play key role in sepsis, regulates 
G2/M cell-cycle progression 
(Cornell, 
Rodenhouse 
et al. 2010, 
Lawan, Al-
Harthi et al. 
2011) 
DUSP5 hVH-3, B23                                            Nuclear ERK>>JNK, p38 
MAPK  





DUSP6 MKP-3, Pst1, rVH-6                  Cytosolic ERK>>JNK, p38 
MAPK  
Essential for embryo 




Jiao, Feng et 
al. 2012) 
DUSP7 MKP-x, Pyst2, B59                          Cytosolic                              ERK>p38 
MAPK>>JNK  
Plays a role in proliferation (Huang and 
Tan 2012) 
DUSP9 MKP-4, Pyst3                                  Nuclear and cytosolic  ERK>>p38 
MAPK>JNK  
Role in insulin signaling and 
placental growth 
(Bazuine, 
Carlotti et al. 
2004, 
Emanuelli, 
Eberle et al. 
2008) 
DUSP10 MKP-5                                                    Nuclear and cytosolic  p38 
MAPK>JNK>>ERK      
Play key role in immunity and 
muscle stem function and 
insulin resistance 
(Shi, Verma 
et al. 2013, 
Zhang, 
Nguyen et al. 
2015) 
DUSP8 hVH-5, M3/6, HB5                              Nuclear and cytosolic  JNK=p38 
MAPK>>ERK   
Unknown  
DUSP16 MKP-7, MKP-M                                 Cytosolic JNK=p38 
MAPK>>ERK      
Regulates differentiation and 






Xavier et al. 
2014) 
      
not ERK1/2 and shuttle between the cytoplasm and 
nucleus (Tonks 2013).       
The expression, activity and function of the MKPs are 
subject to various levels of regulation. For example, 
transcriptional activation and protein stability is 
mediated by MAPKs themselves in addition to reactive 
oxygen species that directly inactivate the catalytic site 
within the MKPs (Caunt and Keyse 2012). Although, 
there is reasonable amount of information on the 
biochemical properties of MKPs, the body of literature 
regarding their physiological function is still 
developing. This review will focus on the prototype 
family member of the MKPs, MKP-1. The current 
works on MKP-1 physiological functions and some of 
the pathophysiological implications of dysregulated 
MKP-1 signaling will be discussed. 
MKP-1/DUSP1 in vitro and in vivo studies 
MKP-1 similarly termed DUSP1, the prototype 
member of MKP family was identified as an 
immediate-early response gene (Keyse and Emslie 
1992, Keyse and Ginsburg 1993). MKP-1, a type I 
member, is widely expressed in many tissues and cells 
and is selective for JNK and p38 MAPK over ERK in 
vitro and in vivo (Wu and Bennett 2005, Lawan, Shi et 
al. 2012). MKP-1 is the most studied MKP family 
member and important physiological function has been 
demonstrated both in cell type specific context and 
various tissue systems. Many studies have established 
MKP-1 as major regulator of numerous physiological 
and pathophysiological roles in the immune system, 
metabolic and cardiovascular systems. More recently 
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there are some studies suggesting a role for MKP-1 in 
the nervous and musculoskeletal systems. 
  Studies have established that MKP-1 is a negative 
regulator of MAPK-mediated inflammatory responses 
(Chi, Barry et al. 2006). MKP-1 plays a major role in 
the regulation of macrophage function and cytokine 
production and innate immune responses (Salojin, 
Owusu et al. 2006, Murray and Wynn 2011) in addition 
to protecting mice from lethal endotoxic shock 
(Hammer, Mages et al. 2006). Furthermore, some other 
studies suggest that MKP-1 is involved in exercise 
training mediated immune remodeling that could be 
beneficial for athletes (Rastogi, Du et al. 2011). There 
is a large body of evidence that implicates MAPKs in 
regulating metabolic signaling and contributing to 
metabolic syndrome (Sabio, Cavanagh-Kyros et al. 
2009, Sabio, Kennedy et al. 2010, Manieri and Sabio 
2015). Similarly, reports have indicated that MKP-1 
plays an important role in metabolism. Findings from 
our lab have shown that MKP-1 deletion mice had 
increased ERK, JNK and p38 MAPK activities in 
insulin-responsive tissues in comparison to wild-type 
littermates (Wu, Roth et al. 2006, Roth, Le et al. 2009). 
Most importantly, this study established that MKP-1 
whole-body knock-out (KO) mice are resistant to diet-
induced obesity because of increased energy 
expenditure and are protected from the development of 
hepatic steatosis (Wu, Roth et al. 2006). In order to 
further investigate the mechanism by which MKP-1 
regulate lipid homeostasis we utilized MKP-1 KO that 
were intercrossed with leptin receptor deficient mice. 
These studies demonstrated that db/db;mkp-1-/- 
hepatocytes were less steatotic in comparison with  
db/db;mkp-1+/+     and also had a significant increase in  
hepatic triglyceride content (Flach, Qin et al. 2011). 
The resistance to the development of hepatic steatosis 
could be partly due to enhanced hepatic triglyceride 
and -oxidation observed in the db/db;mkp-1-/- 
hepatocytes. Although these studies are milestone in 
defining the role of MKP-1 in metabolism, however, 
none of these previous approaches have been effective 
in clarifying the exact tissue contribution of MKP-1 to 
whole-body metabolism. More recently using tissue-
specific deletion strategies we have used the Cre-loxP 
strategy to assess the contribution of MKP-1 in liver in 
the control of metabolism and glucose homeostasis. 
Our current work have demonstrated that liver-specific 
deletion of MKP-1 enhances gluconeogenesis and 
causes hepatic insulin resistance while selectively 
conferring protection from hepatosteatosis upon high 
fat feeding (Lawan, Zhang et al. 2015). These studies 
established that MKP-1 is a major regulator of 
metabolic homeostasis. 
 
The physiological role of this phosphatase has been 
investigated in other tissues systems. MKP-1 has been 
implicated in regulating processes such as glial cell 
function, neuronal cell development and apoptosis 
(Ndong, Landry et al. 2012). Similarly, decreased 
MKP-1 levels have been reported in some neurological 
disorders such as multiple sclerosis, Huntington’s 
disease, cerebral hypoxia and ischemia (Taylor, Moser 
et al. 2013), in addition to playing a role in major 
depressive disorder (Duric, Banasr et al. 2010). 
Another area that MAPK have been involved is 
artherosclerosis, which is one of the leading causes of 
cardiovascular related diseases (Ricci, Sumara et al. 
2004). Equally, some studies have demonstrated a role 
for MKP-1 in the pathogenesis of artherosclerosis 
(Imaizumi, Grijalva et al. 2010). Other reports have 
shown that MKP-1 plays a key role in the development 
of dystrophic muscle diseases (Shi, Boadu et al. 2010) 
and regulation of bone homeostasis (Carlson, Zhang et 
al. 2009). The role of MKP-1 in cancer has also been 
explored, a review of the literature shows that MKP-1 
expression is generally enhanced in a number of human 
tumors such as gastric adenocarcinoma, breast cancer, 
non-small cell carcinoma, prostate carcinoma and 
pancreatic carcinoma (Wang, Cheng et al. 2003, 
Arnoldussen and Saatcioglu 2009, Bai, Xu et al. 2012) 
while in some other type of cancers such as pancreatic 
cancer and oral squamous cell carcinoma the 





Taken together, although MKP-1 is the most studied 
MKP family member there is extensive possibility for 
further research to elucidate the physiological and 
pathophysiological roles of MKP-1. Since phenotype of 
global knockouts are difficult to interpret and 
considering the development of tissue-specific 
knockouts, it will be interesting to examine tissue-
specific contribution of MKP-1 especially in the 
immune and metabolic systems where MKP-1 has been 
established to play major role. Future works should 
explore the precise role of MKP-1 in other tissue 
systems including the cardiovascular and 
musculoskeletal systems, brain and cancer. These 
studies could unravel novel therapeutic approaches to 
target MKP-1 in many disease conditions. 
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